Hodis H N, Mack W J, Azen S P, Alaupovic P, Pogoda J M, LaBree L, Hemphill L C, Kramsch D M, Blankenhorn D H
Atherosclerosis Research Institute, University of Southern California School of Medicine, Los Angeles 90033.
Circulation. 1994 Jul;90(1):42-9. doi: 10.1161/01.cir.90.1.42.
The Monitored Atherosclerosis Regression Study, a randomized, double-blind, placebo-controlled, 2-year trial of lovastatin monotherapy, found that coronary lesions < 50% diameter stenosis (%S) and coronary lesions > or = 50% S at baseline had different responses to therapy. We now report on clinical, lipid, and nonlipid risk factors of treatment response in these lesion subsets.
Two hundred seventy subjects, 37 to 67 years old, with plasma total cholesterol (TC) 190 to 295 mg/dL (4.91 to 7.63 mmol/L) and total triglyceride < 500 mg/dL (5.65 mmol/L) were randomized to low-fat, low-cholesterol diet and either lovastatin 80 mg/d or placebo. Logistic regression was used to model the association between risk factors and coronary lesion progression in mild/moderate (< 50% S) and severe (> or = 50% S) lesions in 220 angiogram pairs analyzed by computer quantitative coronary angiography. In the placebo group, risk factors (P < .05) for the progression of mild/moderate lesions were triglycerides and TC/high-density lipoprotein cholesterol (HDL-C). Risk factors for the progression of severe lesions were HDL-C (negative), low-density lipoprotein cholesterol (LDL-C)/HDL-C, and TC/HDL-C. TC/HDL-C was the predominant risk factor for both mild/moderate and severe lesions in the multivariate analysis. In the lovastatin group, with aggressive lowering of LDL-C and TC below 85 mg/dL and 156 mg/dL, respectively, risk factors for mild/moderate lesions included triglycerides and very-low-density lipoprotein-LDL-associated apolipoprotein C-III (apo C-III-heparin precipitate), a marker of triglyceride-rich lipoprotein particles. Apo C-III-heparin precipitate was the predominant risk factor in the multivariate analysis. Risk factors for severe lesions were LDL-C, LDL-C/HDL-C, TC/HDL-C, and apo B; LDL-C/HDL-C was the predominant risk factor.
These results indicate that triglyceride-rich lipoproteins and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression, respectively. These results add to the growing evidence of the importance of triglyceride-rich lipoproteins as a risk factor for coronary artery disease and the need for treatment in the progression of atherosclerosis.
“监测动脉粥样硬化消退研究”是一项随机、双盲、安慰剂对照的洛伐他汀单药治疗2年试验,发现基线时直径狭窄<50%(%S)的冠状动脉病变和直径狭窄≥50%的冠状动脉病变对治疗有不同反应。我们现在报告这些病变亚组中治疗反应的临床、血脂和非血脂危险因素。
270名年龄在37至67岁之间、血浆总胆固醇(TC)为190至295mg/dL(4.91至7.63mmol/L)且总甘油三酯<500mg/dL(5.65mmol/L)的受试者被随机分配至低脂、低胆固醇饮食组,并分别接受80mg/d洛伐他汀或安慰剂治疗。采用逻辑回归对通过计算机定量冠状动脉造影分析的220对血管造影中轻度/中度(<50%S)和重度(≥50%S)病变的危险因素与冠状动脉病变进展之间的关联进行建模。在安慰剂组中,轻度/中度病变进展的危险因素(P<0.05)为甘油三酯和TC/高密度脂蛋白胆固醇(HDL-C)。重度病变进展的危险因素为HDL-C(负相关)、低密度脂蛋白胆固醇(LDL-C)/HDL-C和TC/HDL-C。在多变量分析中,TC/HDL-C是轻度/中度和重度病变的主要危险因素。在洛伐他汀组中,随着LDL-C和TC分别积极降低至85mg/dL和156mg/dL以下,轻度/中度病变的危险因素包括甘油三酯和极低密度脂蛋白-LDL相关载脂蛋白C-III(apo C-III-肝素沉淀),这是富含甘油三酯脂蛋白颗粒的标志物。在多变量分析中,apo C-III-肝素沉淀是主要危险因素。重度病变的危险因素为LDL-C、LDL-C/HDL-C、TC/HDL-C和载脂蛋白B;LDL-C/HDL-C是主要危险因素。
这些结果表明,富含甘油三酯的脂蛋白和富含胆固醇的脂蛋白分别对轻度/中度和重度病变进展有不同影响。这些结果进一步证明了富含甘油三酯的脂蛋白作为冠状动脉疾病危险因素的重要性,以及在动脉粥样硬化进展中进行治疗的必要性。